Breast cancer rather presents distinct subtypes associated with different clinicaloutcomes. Understanding this heterogeneity is a key factor for the developmentof targeted preventative and therapeutic interventions (Rakha et al 2008). 18Ffluoro-2-deoxy-D-glucose Positron Emission Tomography (18F-FDG PET) hasbeen evaluated in breast cancer to characterize primary tumors, lymph nodestaging and patients follow-up after surgery, chemotherapy and/or externalradiotherapy (Lind et al 2004). PET is a molecular imaging technique sensitiveto functional or metabolic changes in tissues. Since functional changes precedeanatomical changes, FDG PET has the capability to detect viable tumor tissueearly through its elevated glucose metabolism in comparison with thesurrounding normal tissues (Plathow et al 2008). A major advantage of FDGPET imaging compared to conventional imaging is that it screens the entirepatient for local recurrence, lymph node metastases and distant metastasesduring a single whole-body examination using a single injection of tracer, with areported average sensitivity and specificity of 96% and 77%, respectively(Scheidhauer et al 2004). A general limitation of this new application of thistechnology are false negative results ( not all breast cancer patients are positiveto 18F FDG PET analysis) and interpretative pitfalls due to physiological tracerdistributions. Proteomic and transcriptomic platforms both play important rolesin cancer research, with differing strengths and limitations. Here, we describe aproteo-transcriptomic integrative strategy to profile patients positive andnegative to PET analysis by combining differentially expressed proteins withgene expression profile. In this study, 2D-Difference in Gel Electrophoresis(2D-DIGE), mass spectrometry and DNA-microarray analysis by Agilentplatform, performed on the same sample, were utilized to compare patientspositive and negative to 18F-FDG PET analysis. Our study illustrates how thesystematic integration of proteomic and transcriptomic data could open newavenues to improve diagnosis and follow up and to accelerate cancer biomarkersdiscovery.
|Titolo della pubblicazione ospite||Genomic and Proteomic Integrated Approach to Study Breast Cancer: Differences in Patients negative and Positive to 18F-FDG PET Screening|
|Numero di pagine||8|
|Stato di pubblicazione||Published - 2012|
Bravata', V. (2012). Genomic and Proteomic Integrated Approach to Study Breast Cancer: Differences in Patients negative and Positive to 18F-FDG PET Screening. In Genomic and Proteomic Integrated Approach to Study Breast Cancer: Differences in Patients negative and Positive to 18F-FDG PET Screening